Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo

OBJECTIVE: To evaluate the efficacy of Taselisib, a selective inhibitor of PIK3CA, against primary uterine serous carcinomas (USC) harboring PIK3CA mutations and HER2/neu gene amplification. METHODS: Sensitivity to taselisib was evaluated by flow-cytometry viability assays in vitro against nine prim...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: Lopez, Salvatore, Schwab, Carlton L., Cocco, Emiliano, Bellone, Stefania, Bonazzoli, Elena, English, Diana P., Schwartz, Peter E., Rutherford, Thomas, Angioli, Roberto, Santin, Alessandro D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4270135/
https://ncbi.nlm.nih.gov/pubmed/25172762
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2014.08.024
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados